InflaRx (NASDAQ:IFRX) Shares Down 2.3% – Should You Sell?

Posted by George Bondi on Jul 29th, 2026

InflaRx N.V. (NASDAQ:IFRX – Get Free Report)’s stock price was down 2.3% on Monday . The company traded as low as $1.68 and last traded at $1.70. 928,388 shares changed hands during mid-day trading, a decline of 28% from the average daily volume of 1,288,831 shares. The stock had previously closed at $1.74.

Wall Street Analyst Weigh In

IFRX has been the topic of several research analyst reports. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald upped their target price on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Guggenheim restated a “buy” rating and issued a $14.00 price objective on shares of InflaRx in a research note on Tuesday, April 21st. Oppenheimer initiated coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Finally, Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Get Our Latest Stock Report on InflaRx

InflaRx Stock Performance

The company has a market capitalization of $119.28 million, a P/E ratio of -2.32 and a beta of 2.44. The company has a 50-day simple moving average of $2.02 and a 200 day simple moving average of $1.49.

InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. As a group, sell-side analysts forecast that InflaRx N.V. will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. Boothbay Fund Management LLC increased its stake in InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after acquiring an additional 17,056 shares during the period. Concurrent Investment Advisors LLC raised its holdings in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares in the last quarter. Eversept Partners LP lifted its position in shares of InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after acquiring an additional 26,677 shares during the period. Finally, Squarepoint Ops LLC lifted its position in shares of InflaRx by 29.1% in the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock worth $253,000 after acquiring an additional 42,489 shares during the period. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

(Get Free Report)

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.